瘦素治疗肥胖:以前的失败,有希望的未来
Avraham Marcucci1, Jamie Mullally2, William H Frishman1
1From the Department of Internal Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.
Cardiology in review
|June 19, 2025
概括
瘦素是一种关键的肥胖研究激素,显示出新组合疗法的潜力. 用勒和GLP-1激动剂向下丘脑神经元可能会减少食物摄入量和体重.
科学领域:
- 内分泌学 在内分泌学.
- 代谢研究研究 代谢研究
- 神经科学是一个神经科学.
背景情况:
- 1950年发现的瘦素对调节能量平衡和肥胖生理学至关重要.
- 再组合勒在缺陷模型中有效降低体重,但在饮食诱导的肥胖症中面临阻力.
- 之前的阿米林组合疗法表现有前途,但遇到了抗体发育问题.
研究的目的:
- 探索肥胖管理的新型治疗策略.
- 为了研究丁与其他药物结合的疗效.
- 确定减肥疗法的新目标.
主要方法:
- 历史和最近的肥胖研究结果的审查.
- 分析素在能量平衡和体重调节中的作用.
- 检查组合治疗方法,包括丁与氨酸和GLP-1受体激活剂.
主要成果:
- 瘦素对能量平衡至关重要,尽管瘦素耐药性限制了其在饮食引起的肥胖症中的使用.
- 组合疗法,如丁与氨酸,已显示增强减肥.
- 新兴研究表明,将瘦素与GLP-1受体激动剂结合使用可能会减少食物摄入量和体重.
结论:
- 瘦素仍然是肥胖研究和治疗的关键因素.
- 组合疗法提供了一个有希望的途径,以克服勒素耐药性.
- 针对特定的下丘脑神经元,使用勒和GLP-1激动剂,为体重管理提供了一个潜在的策略.
相关概念视频
Glucagon-like Receptor Agonists
435
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
435
Obesity
627
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
627
Regulation of Food Intake
533
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
533
Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
Overview of Lipid Metabolism
2.6K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
2.6K
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271


